Executive Interviews

  1. Best Board Practices From 4 Seasoned Execs 2/1/2022

    Considering we’ve received numerous questions regarding joining and working with corporate boards, we decided to create an expanded “Ask The Board” article for this month to serve as a resource to our readers.

  2. The Story Of An Accidental Life Science CEO 2/1/2022

    While some elements of Bernard Coulie’s first startup experience left a bad taste in his mouth, he still enjoyed having the opportunity to work on front-running technology — not what’s trendy at the time, but what’s going to be hot in the future. That’s what led him to Pliant Therapeutics.

  3. Will Pyxis Oncology Be Pfizer's Fourth Billion-Dollar Spinout? 1/4/2022

    After working at Pfizer and being instrumental in the SpringWorks spinout, Lara Sullivan, M.D., is no stranger to building pharma companies. But getting to where she is today as CEO of Pyxis Therapeutics hasn’t come without its challenges.

  4. What's The Outlook From Life Science Operations For 2022 — And Beyond? 12/1/2021

    With the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems leaders in biopharma manufacturing have never faced a greater challenge. Here’s what 12 of those execs have to say as they look to 2022 and beyond.

  5. What's The Biopharma Financial View For 2022? 12/1/2021

    Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.

  6. Reflection And Projection 2.0 — 15 CEOs Map Biopharma's Present And Future 12/1/2021

    In this outlook article with 15 biopharma CEOs, they talk about everything from trends to watch, to disruptive innovations to the effects and future of remote work on the industry.

  7. Can the FDA & CDC Recover from Recent Politics? 12/1/2021

    Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.

  8. Formulation Alternatives: Looking Beyond Parenteral Biologics 12/1/2021

    2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and efficacy hurdles, market forecasts are rising fast.

  9. These Professionals Are Creating Our Outsourcing Future 12/1/2021

    While asking executives their views on the future of outsourcing drug development and manufacturing, I arrived at an epiphany of sorts: They are the future of biopharma outsourcing.

  10. Is Janssen's Pathway Approach The Future Of Drug Development 12/1/2021

    Two Janssen execs talk about the future of what they call a pathway approach to developing new medicines, which attempts to match the biology of a pathway to unmet medical need for patients, across a broad range of immune-mediated, inflammatory disease.